<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04043702</url>
  </required_header>
  <id_info>
    <org_study_id>12345678</org_study_id>
    <nct_id>NCT04043702</nct_id>
  </id_info>
  <brief_title>Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity</brief_title>
  <official_title>Combination of Topiramate(Conviban) and Empagliflozin(Jardiance) is Considered a Good Option for the Treatment of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health and Population, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health and Population, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim was to show if a combination of topiramate and empagliflozin have the greatest weight
      decreasing effect in comparison to each drug alone and to group with no treatment( control
      group).

      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim was to show if a combination of topiramate and empagliflozin have the greatest weight
      decreasing effect in comparison to each drug alone and to group with no treatment( control
      group).

      Materials and methods 200 obese patients 4 groups. had been monitored in a private clinic,
      each group 50 patients number, with 35 females and 15 males who were already on treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2019</start_date>
  <completion_date type="Actual">July 29, 2019</completion_date>
  <primary_completion_date type="Actual">July 20, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>change in weight</measure>
    <time_frame>6 months</time_frame>
    <description>weight measurement</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>on topiramate</arm_group_label>
    <description>&quot;topiramate&quot;, &quot;conviban速&quot; group vs no treatment ( control group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>on empagliflozine</arm_group_label>
    <description>&quot;empagliflozine&quot;, &quot;jardiance速&quot; vs no treatment ( control group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>on topiramate plus empagliflozine</arm_group_label>
    <description>all patients' vs no treatment ( control group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <description>all patients' vs no treatment ( control group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The intervention being studied</intervention_name>
    <description>Intervention Other Names have not been specified</description>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_label>on empagliflozine</arm_group_label>
    <arm_group_label>on topiramate</arm_group_label>
    <arm_group_label>on topiramate plus empagliflozine</arm_group_label>
    <other_name>&quot;empagliflozine&quot;, &quot;jardiance速&quot;)</other_name>
    <other_name>&quot;topiramate&quot;, &quot;conviban速&quot;</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        obese peoples , age from 35 to 55 years
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. stable weight in the previous 6 months.

          2. a sedentary lifestyle.

          3. no history of diabetes mellitus.

          4. taking medication that affects appetite, or weight within the past 6 months

        Exclusion Criteria:

          1. severe anemia

          2. hypothyroidism and hyperthyroidism

          3. Diabetes mellitus

          4. moderate to severe liver or kidney disease

          5. body mass index less than 30
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mahmoud younis, M.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>egyptian ministry of health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mahmoud Younis</name>
      <address>
        <city>Cairo</city>
        <zip>11759</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2019</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>mahmoud younis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>drug combination</keyword>
  <keyword>empagliflozin(jardiance)</keyword>
  <keyword>topiramate(conviban)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>September 17, 2019</submitted>
    <returned>October 9, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

